Nevertheless, the development of KEAP1-NRF2 PPI inhibitors as therapeutic agents for AD faces significant difficulty, including poor BBB penetration, high polarity, low stability, and limited bioavailability [117,118]. This evidence concerns the gene KEAP1 and Alzheimer disease.